Evidence map›Paper›PMID 38640229›Full record

ArticleCancer research2024

GPR1 and CMKLR1 Control Lipid Metabolism to Support the Development of Clear Cell Renal Cell Carcinoma.

Dazhi Wang, Iqbal Mahmud, Vijay S Thakur, Sze Kiat Tan, Daniel G Isom, David B Lombard, Mark L Gonzalgo, Oleksandr N Kryvenko, Philip L Lorenzi, Vanina T Tcheuyap and 2 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Dazhi WangDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0001-9889-8290
Iqbal MahmudDepartment of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7729-8122
Vijay S ThakurDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0001-5298-963X
Sze Kiat TanDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0001-9653-555X
Daniel G IsomDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0001-5637-2370
David B LombardSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0002-4292-0185
Mark L GonzalgoSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0003-0476-0288
Oleksandr N KryvenkoDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0001-5731-1748
Philip L LorenziDepartment of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-0385-7774
Vanina T TcheuyapKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-6817-9241
James BrugarolasKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-8575-499X
Scott M WelfordDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida.ORCID 0000-0002-9579-4223
University of Miami · USThe University of Texas MD Anderson Cancer Center · USThe University of Texas Southwestern Medical Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
University of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7M
Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI George S. Grills · 2019 to 2026
$24.1M
UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeff G McDonald · 2022 to 2026
$7.4M
pH regulation of cell surface receptorsR35GM119518 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel Isom · 2016 to 2026
$4.1M
Regulation of one carbon metabolism and epigenetics by SIRT5R01GM101171 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOMBARD, DAVID BENNER · 2012 to 2021
$2.6M
SIRT5 inhibitors and degraders as novel treatments for Ewing sarcomaR01CA253986 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Benner Lombard, NOURI NEAMATI · 2022 to 2026
$2.1M
Adipokine Signaling as a Therapeutically Targetable Driver of Tumor MetabolismR01CA254409 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WELFORD, SCOTT MICHAEL · 2021 to 2025
$1.8M
Computational Tools for Analysis and Visualization of Quality Control Issues in Metabolomic DataU01CA235510 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AKBANI, REHAN, BROOM, BRADLEY MCINTOSH · 2018 to 2021
$1.6M
Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and MetabolomicsS10OD012304 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAWKE, DAVID H · 2013 to 2013
$877k
Cancer Prevention and Research Institute of Texas (CPRIT) RP130397Florida Department of Health (DOH) JEK Grant 21K07National Cancer Institute (NCI) CA253986National Cancer Institute (NCI) CA254409National Cancer Institute (NCI) P30CA240139National Cancer Institute (NCI) S10OD012304-01National Institute of General Medical Sciences (NIGMS) GM101171National Institute of General Medical Sciences (NIGMS) R35GM119518NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA240139NCI NIH HHS P50 CA196516NCI NIH HHS R01 CA253986NCI NIH HHS R01 CA254409NCI NIH HHS U01 CA235510NIDDK NIH HHS P30 DK127984NIGMS NIH HHS R01 GM101171NIGMS NIH HHS R35 GM119518NIH HHS S10 OD012304
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, is largely incurable in the metastatic setting. ccRCC is characterized by excessive lipid accumulation that protects cells from stress and promotes tumor growth, suggesting that the underlying regulators of lipid storage could represent potential therapeutic targets. Here, we evaluated the regulatory roles of GPR1 and CMKLR1, two G protein-coupled receptors of the protumorigenic adipokine chemerin that is involved in ccRCC lipid metabolism. Both genetic and pharmacologic suppression of either receptor suppressed lipid formation and induced multiple forms of cell death, including apoptosis, ferroptosis, and autophagy, thereby significantly impeding ccRCC growth in cell lines and patient-derived xenograft models. Comprehensive lipidomic and transcriptomic profiling of receptor competent and depleted cells revealed overlapping and unique signaling of the receptors granting control over triglyceride synthesis, ceramide production, and fatty acid saturation and class production. Mechanistically, both receptors enforced suppression of adipose triglyceride lipase, but each receptor also demonstrated distinct functions, such as the unique ability of CMKLR1 to control lipid uptake through regulation of sterol regulatory element-binding protein 1c and the CD36 scavenger receptor. Treating patient-derived xenograft models with the CMKLR1-targeting small molecule 2-(α-naphthoyl) ethyltrimethylammonium iodide (α-NETA) led to a dramatic reduction in tumor growth, lipid storage, and clear-cell morphology. Together, these findings provide mechanistic insights into lipid regulation in ccRCC and identify a targetable axis at the core of the histologic definition of this tumor that could be exploited therapeutically. Significance: Extracellular control of lipid accumulation via G protein receptor-mediated cell signaling is a metabolic vulnerability in clear cell renal cell carcinoma, which depends on lipid storage to avoid oxidative toxicity.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsLipid MetabolismReceptors, ChemokineReceptors, G-Protein-CoupledAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceSignal TransductionXenograft Model Antitumor AssaysCMKLR1 protein, humanGPR1 protein, humanReceptors, ChemokineReceptors, G-Protein-Coupled

Identifiers

PMID38640229
PMCPMC11290988
OpenAlexW4394951179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.